nach oben

psychopraxis. neuropraxis

Erschienen in:

01.09.2016 | Psychiatrie

Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen

verfasst von: Univ.-Prof. Dr. Luise Poustka

Erschienen in: psychopraxis. neuropraxis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autismus-Spektrum-Störungen (ASS) galten lange als Ausschlusskriterium für die Diagnose einer ADHS. Nach DSM-5 besteht nun die Möglichkeit, eine ADHS zusammen mit ASS zu diagnostizieren. Kinder mit der Doppeldiagnose ASS + ADHS zeigen insgesamt mehr Beeinträchtigungen sowohl hinsichtlich ihrer allgemeinen Psychopathologie als auch ihres Funktionsniveaus. Durch die Differenzierung von Patienten mit ASS mit zusätzlicher ADHS-Symptomatik und Patienten ohne ADHS-Symptomatik wird klinisch eine differenzierte Behandlung der individuellen Psychopathologie erleichtert. In folgendem Beitrag werden evidenzbasierte Therapieoptionen, vor allem in pharmakologischer Hinsicht, für von beiden Störungen Betroffene dargestellt.

Vorheriger Artikel Panorama

Nächster Artikel M. Parkinson: L-Dopa nach wie vor wirksamste Therapie

Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196–1205CrossRefPubMed

Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence o disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet 368(9531):210–215CrossRefPubMed

Bloch M, Qawasmi A (2011) Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50(10):991–1000CrossRefPubMedPubMedCentral

Choque Olsson N, Rautio D, Asztalos J, Stoetzer U, Bölte S (2016) Social skills group training in high-functioning autism: a qualitative responder study. Autism. doi:10.1177/1362361315621885

Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F (2012) Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 12(4):461–73

Di Martino A, Melis G, Cianchetti C, Zuddas A (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 14:207–218CrossRefPubMed

Fernández de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 54(1):62–70CrossRefPubMedPubMedCentral

Friedrich EV, Sivanathan A, Lim T, Suttie N, Louchart S, Pillen S, Pineda JA (2015) An effective neurofeedback intervention to improve social interactions in children with autism spectrum disorder. J Autism Dev Disord 45(12):4084–4100. doi:10.1007/s10803-015-2523-5 CrossRefPubMed

Gadow KD, Devincent CJ, Pomeroy J (2006) ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 36:271–283CrossRefPubMed

10.

Grzadzinski R, Di Martino A, Brady E et al (2010) Examining autistic traits in children with ADHD: Does the autism spectrum extend to ADHD? J Autism Dev Disord 41(9):1178–1191. doi:10.1007/s10803-010-1135-3 CrossRef

11.

Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255CrossRefPubMed

12.

Harfterkamp M, van de Loo-Neus Minderaa GR et al (2012) A randomized doubleblind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 51:733–741CrossRefPubMed

13.

Hartley S, Sikora D (2009) Which DSM-IV-TR criteria best differentiate high-functioning autism spectrum disorder from ADHD and anxiety disorders in older children? Autism 13(5):485–509PubMedPubMedCentral

14.

Holtmann M, Sonuga-Barke E, Cortese S, Brandeis D (2014) Neurofeedback for ADHD. Child Adolesc Psychiatr Clin N Am 23(4):789–806CrossRefPubMed

15.

Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S (2011) Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 53(11):986–993CrossRefPubMed

16.

Holtmann M, Bolte S, Poustka F (2007) Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology 40:172–177CrossRefPubMed

17.

Iizuka C, Yamashita Y, Nagamitsu S, Yamashita T, Araki Y, Ohya T et al (2010) Comparison of the strengths and difficulties questionnaire (SDQ) scores between children with high-functioning autism spectrum disorder (HFASD) and attention-deficit/hyperactivity disorder (AD/HD). Brain Dev 32(8):609–612CrossRefPubMed

18.

James S, Montgomery P, Williams K (2011) Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 9:CD007992

19.

Jahromi LB, Kasari CL, McCracken JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395–404CrossRefPubMed

20.

McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah B, McDougle CJ, Nurmi EL (2014) Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 14(3):295–302CrossRefPubMed

21.

Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T et al (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6(1):18CrossRefPubMedPubMedCentral

22.

Nijmeijer JS, Arias-Vasquez A, Rommelse NN et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685PubMedPubMedCentral

23.

Penzner JB, Dudas M, Saito E et al (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563–573CrossRefPubMedPubMedCentral

24.

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948 (Review)CrossRefPubMed

25.

Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599–610CrossRefPubMed

26.

Rao PA, Landa RJ (2013) Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism 18:272–280CrossRefPubMedPubMedCentral

27.

Reichow B, Steiner A, Volkmar F (2012) Cochrane Review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child Health 8(2):266–315CrossRef

28.

Ronald A, Simonoff E, Kuntsi J et al (2008) Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry 49:535–542CrossRefPubMed

29.

RUPP Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266–1274CrossRef

30.

Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 32:575–583

31.

Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ, Research Units on Pediatric Psychopharmacology Autism Network (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 172(12):1197–1206. doi:10.1176/appi.ajp.2015.15010055 CrossRefPubMed

32.

Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921–929CrossRefPubMed

33.

Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 54(5):527–535CrossRefPubMed

34.

Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol 16:611–619CrossRefPubMed

35.

Yoshida Y, Uchiyama T (2004) The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 13(5):307–314CrossRefPubMed

Titel: Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen
verfasst von: Univ.-Prof. Dr. Luise Poustka
Publikationsdatum: 01.09.2016
Verlag: Springer Vienna
Erschienen in: psychopraxis. neuropraxis / Ausgabe 4/2016
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI: https://doi.org/10.1007/s00739-016-0337-7

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Aktuelle Therapiemöglichkeiten

Angstbewältigung

Fortschritte der letzten Jahrzehnte

aktuell

Benzodiazepine im Fokus

Das Restless-Legs-Syndrom